Roche Vabysmo PFS approved in EU for three retinal conditions

Roche (RHHBY) announced that the European Medicines Agency, EMA, has approved Vabysmo 6.0 mg single-dose prefilled syringe, PFS, for use in the treatment of neovascular or ‘wet’ age-related macular degeneration, nAMD, diabetic macular edema, DME, and macular edema following retinal vein occlusion, RVO. Together, these three conditions affect more than nine million people in the European Union. “Approval of the Vabysmo prefilled syringe in the EU offers a convenient way for ophthalmologists to administer this treatment for people with three of the most common causes of vision loss,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “This simplified administration may thereby help reduce the treatment burden for patients and retina specialists.”